Could a new PET scan help match pancreatic cancer patients to the right therapy?
NCT ID NCT03851237
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the scan could predict how well patients would respond to standard chemotherapy or a CCR2-targeted therapy, potentially helping doctors choose the best treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
64Cu-DOTA-ECL1i (a radioactive imaging agent)
What this could lead to
If successful, this imaging test could help doctors identify which pancreatic cancer patients are likely to respond to CCR2-targeted therapy, avoiding ineffective treatments.
What could go wrong
This is an early phase 1 study with only 69 participants, so the imaging agent may not reliably predict treatment response in larger, more diverse groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States